GlassScriptPhysician profile
Paul A Monaco
NPI 1366436537
$2,946.98
in general payments reported to CMS, 2019-2025
32 companies · $456 in 2025
The $456 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $763 · 2020: $914 · 2021: $195 · 2022: $48.94 · 2023: $171 · 2024: $398 · 2025: $456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,025.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,025.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $335.70 | 2019-2025 | Wegovy, Ozempic |
| Glaxosmithkline, LLC. | $288.74 | 2019-2023 | Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $275.06 | 2019-2025 | Mounjaro, Zepbound |
| Amgen INC. | $247.30 | 2019-2025 | Evenity, Prolia, Enbrel |
| Amarin Pharma, INC. | $226.27 | 2019-2020 | |
| Pfizer INC. | $171.45 | 2019-2024 | |
| Janssen Biotech, INC. | $171.12 | 2024-2025 | Tremfya |
| Janssen Pharmaceuticals, INC | $120.83 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $111.63 | 2024-2025 | Orencia |
| Abbvie INC. | $91.80 | 2020-2024 | |
| Sunovion Pharmaceuticals INC. | $77.38 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $77.14 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $73.41 | 2019-2024 | Capvaxive |
| Eisai INC. | $70.11 | 2020-2021 | |
| Astellas Pharma US INC | $69.30 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $67.38 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $55.66 | 2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.34 | 2019-2025 | Jardiance |
| Scilex Pharmaceuticals INC. | $53.22 | 2019 | |
| Avanir Pharmaceuticals, INC. | $47.62 | 2020-2022 | |
| Ultragenyx Pharmaceutical INC. | $32.17 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $30.07 | 2019-2023 | |
| Amneal Pharmaceuticals LLC | $26.81 | 2025 | Unithroid |
| Kowa Pharmaceuticals America, INC. | $24.85 | 2019 | |
| Boston Scientific Corporation | $24.72 | 2020 | |
| Acorda Therapeutics, INC | $23.40 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.79 | 2025 | Takhzyro |
| Biohaven Pharmaceutical Holding Company LTD. | $17.84 | 2022 | |
| Allergan, INC. | $17.12 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $15.32 | 2021 | |
| Currax Pharmaceuticals LLC | $14.84 | 2020 | |
| Seqirus USA INC | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Monaco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.